Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KEROL Emulsion is a topical dermatological product containing 50% urea, a potent keratolytic agent. Developed by PharmaDerm (a division of Nycomed US, later acquired by Sandoz), it is specifically formulated for the debridement and promotion of normal healing of hyperkeratotic surface lesions. The emulsion works by gently dissolving the intercellular matrix and increasing skin moisture through the softening and dissolution of keratin, which allows dead skin cells to shed more easily. It is indicated for the treatment of rough or dry skin conditions such as eczema, psoriasis, and keratosis, as well as for softening damaged or dystrophic fingernails and toenails. Launched in 2008, it serves both the dermatology and podiatry markets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KEROL Emulsion.